SCHEMBL22798281

SCHEMBL22798281

CC(=O)Nc1cc(C(=O)NCCSc2ncc(C(F)(F)F)cc2Cl)cc(C)n1

nearest known ligand 0.58

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.58
NPSR1 Q6W5P4 1/20 0.46
KMT2A Q03164 3/20 0.45
PKM P14618 3/20 0.45
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 5/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPK1 P28482 1/20 0.40
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30449608 1.00 SCN9A (0.58) SCN9ANPSR1KMT2APKMMEN1
SCHEMBL22809525 0.91 SCN9A (0.48) SCN9ANPSR1KMT2APKMMEN1
SCHEMBL22798287 0.91 SCN9A (0.56) SCN9ANPSR1KMT2APKMMEN1
SCHEMBL22797815 0.86 SCN9A (0.57) SCN9ANPSR1KMT2APKMMEN1
SCHEMBL30450477 0.86 SCN9A (0.57) SCN9ANPSR1KMT2APKMMEN1
SCHEMBL30449765 0.83 SCN9A (0.59) SCN9ANPSR1KMT2APKMMEN1
SCHEMBL22798301 0.83 SCN9A (0.59) SCN9ANPSR1KMT2APKMMEN1
SCHEMBL22798304 0.83 SCN9A (0.82) SCN9AKMT2AMEN1ALDH1A1LMNA
SCHEMBL22798309 0.83 SCN9A (0.59) SCN9ANPSR1KMT2AMEN1ALDH1A1
SCHEMBL30449741 0.83 SCN9A (0.59) SCN9ANPSR1KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN claimed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP claimed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN claimed
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN disclosed
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers RAQUALIA PHARMA INC. (JP) 2021-10-26 US disclosed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP disclosed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers SCN8A, SCN7A, SCN1A SCN9A 9/4885NPSR1 1348/4885KMT2A 1799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.